The use of laboratory-identified event surveillance to classify adverse outcomes due to


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 24 11 2020
medline: 7 9 2021
entrez: 23 11 2020
Statut: ppublish

Résumé

Adverse outcomes following Clostridioides difficile infection (CDI) are not often reported for long-term care facility (LTCF) residents. We focused on the adverse outcomes due to CDI identified in Alberta LTCFs. All positive Clostridioides difficile stool specimens identified by laboratory-identified (LabID) event surveillance in Alberta from 2011 to 2018, along with Alberta Continuing Care Information System, were used to define CDI in Alberta LTCFs. CDI cases were classified as long-term care onset, hospital onset, and community onset. Laboratory records were linked to provincial databases to analyze acute-care admissions and mortality within 30-day post CDI. Age, sex, case classification, episode, and operator type, were investigated using logistic regression. Overall, 902 CDI cases were identified in 762 LTCF residents. Of all CDI events, 860 (95.3%) were long-term care onset, 38 (4.2%) were hospital onset, and 4 (0.4%) were community onset. The CDI rate was 2.0 of 100,000 resident days. In total, 157 residents (20.6%) had 30-day all-cause mortality, 126 CDI cases (14.0%) had 30-day all-cause acute-care admissions. The 30-day all-cause mortality rate was significantly higher in residents aged >80 versus ≤80 years (24.9 vs 12.3 per 100 residents; P < .05). Residents aged >80 years, with hospital-onset CDI, and those staying in private or voluntary LTCFs were more likely to have 30-day all-cause acute-care admissions. The prevalence of CDI adverse outcomes is in LTCFs was found to be high using LabID event surveillance. Annual review of CDI adverse outcomes using LabID event can minimize the burden of surveillance and standardize the process across all Alberta LTCFs.

Identifiants

pubmed: 33222722
pii: S0899823X20012696
doi: 10.1017/ice.2020.1269
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

557-564

Auteurs

Ye Shen (Y)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.

Jennifer Ellison (J)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.

Jenine Leal (J)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
O'Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.

Kathryn R Bush (KR)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.

A Uma Chandran (AU)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Sumana Fathima (S)

Analytics and Performance Reporting Branch, Alberta Ministry of Health, Edmonton, Alberta, Canada.

John M Conly (JM)

Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
O'Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.
Department of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.
Department of Pathology and Laboratory Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.
Snyder Institute for Chronic Diseases, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH